A global problem
Every year, over 5 million people are diagnosed with cancer in their
digestive system.
The Data-Driven Diagnostics Company
Our unique approach combines expertise in gastrointestinal oncology, digital pathology and AI-driven biomarker discovery.
Rising incidence
One of the deadliest cancers occurs in the esophagus, with cases growing at an alarming rate.
Symptoms like heartburn can cause Barrett’s Esophagus, a precursor to cancer.
9 out of every 10 affected patients are undiagnosed.
Symptoms like heartburn can cause Barrett’s Esophagus, a precursor to cancer.
9 out of every 10 affected patients are undiagnosed.
Poor survival
Some patients with Barrett’s will develop advanced esophageal cancer and have a devastating five-year survival rate of less than 15%.
Diagnostics are the bottleneck
It is impossible to perform an invasive endoscopy on every patient at risk of esophageal cancer.
This needs to change
- 2022
- 2023
- 2024
- 2025
- 2026
Diagnosing cancer
earlier and faster
Our technologies give doctors access to less invasive and better diagnostics for diseases such as Barrett’s esophagus, so we can reduce deaths from late-stage cancer.
Work with the emerging leader in digital diagnostics and transform healthcare
What we do
Cytosponge™
Detecting Esophageal cancer early
The Cytosponge test is a combination of a swallowable pill on a string for cell collection and a diagnostic test to identify patients at risk of esophageal cancer by detecting its precursor: Barrett’s Esophagus.
Cyted Laboratories
Improving patient care
We provide histopathology as a service to public as well as private healthcare providers. Through our unique clinical pathway and data platform, we are positioned to change patient journeys by leveraging pathology data at scale.
